Other
CN
EU
USA
Description: Sorafenib Tosylate (BAY439006; BAY-439006; BAY549085; BAY-549085; Nexavar; SFN), the tosylate salt of Sorafenib which is an approved anticancer medication, is a potent multi-kinase inhibitor of Raf-1, B-Raf and VEGFR-2 with potential antineoplastic activity. It inhibits Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in enzymatic assays, respectively. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis. Sorafenib was approved in 2005 for use in the treatment of advanced renal cancer.
References: Cancer Res, 2004, 64(19), 7099-7109.
Related CAS#: 284461-73-0 (free base)
Product Catalog 2022
Guide to Product Handling
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
Purity ≥98%
COA
MSDS
The number of nuclei breaking the internal limiting membrane (ILM). A: Controlled group; B: ROP group; C: Vehicle-treated ROP group; D: Low doses sorafenib-treated ROP group; E: Middle doses sorafenib-treated ROP group; F: High dose sorafenib-treated ROP group.